Factors affecting an economic model for zoster vaccination

Area of Science:

• Immunization
• Public Health
• Health Economics

Background:

• The Shingles Prevention Study demonstrated that zoster vaccination significantly reduces herpes zoster and post-herpetic neuralgia (PHN).
• The potential for a widespread vaccination program necessitates thorough cost-effectiveness evaluations.
• Current analyses lack robust data on long-term benefits, quality of life impacts, and comprehensive economic modeling.

Purpose of the Study:

• To highlight the need for rigorous cost-effectiveness analyses of zoster vaccination programs.
• To identify key components for economic models, including disease burden and vaccination impact.
• To emphasize the scarcity of economic data on zoster and PHN in unvaccinated populations.

Main Methods:

• Review of existing data on zoster and PHN economic burden.
• Identification of factors for economic modeling: morbidity, quality of life, adverse effects, healthcare costs, and vaccine administration costs.
• Assessment of the need for regional economic impact studies.

Main Results:

• Zoster vaccination reduces the incidence and severity of herpes zoster and PHN.
• Widespread vaccination programs require substantial investment, making cost-effectiveness crucial.
• Robust economic data, particularly for unvaccinated populations and diverse regions, is currently limited.

Conclusions:

• Zoster vaccination offers significant health benefits, reducing shingles and PHN.
• Comprehensive economic evaluations are essential before implementing large-scale vaccination initiatives.
• Further research is required to establish the global economic impact and cost-effectiveness of zoster vaccination strategies.